Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objectives: The aim of this multicentre study was to understand patients' needs and to evaluate the oral ulcer activity with the Composite Index (CI), according to different treatment modalities in Behçet's syndrome (BS).

Methods: BS patients (n=834) from 12 centres participated in this cross-sectional study. Oral ulcer activity (active vs. inactive) and the CI (0: inactive vs. 1-10 points: active) were evaluated during the previous month. The effects of treatment protocols [non-immunosuppressive: non-IS vs. immunosuppressive: (ISs)], severity (mild vs. severe), disease duration (<5 years vs. ≥5 years) and smoking pattern (non-smoker vs. current smoker) were analysed for oral ulcer activity.

Results: Oral ulcer activity was observed in 65.1% of the group (n=543). In both genders, the activity was higher in mild disease course with non-IS treatment group compared to severe course with ISs (p<0.05). As a resistant group, patients with mild disease course whose mucocutaneous symptoms were unresponsive to non-IS medications were treated with ISs in a limited period and achieved the highest CI scores in females. Oral ulcer activity and poor CI score were associated with disease duration less than 5 years compared to others in male patients (p<0.05).

Conclusions: Oral ulcer activity pattern is affected by both the combination of disease course, treatment protocols and disease duration. CI scores reflected the oral clinical activity and CI might be a candidate scale to evaluate the efficacy of treatments during the follow-up of oral ulcer activity in BS.

Download full-text PDF

Source

Publication Analysis

Top Keywords

oral ulcer
12
ulcer activity
12
composite treatment
8
treatment modalities
8
modalities behçet's
8
behçet's syndrome
8
multicentre study
8
activity assessment
4
assessment composite
4
syndrome multicentre
4

Similar Publications

Balance of the oral-intestinal axis microbiota is essential for maintaining oral mucosal health. The occurrence of oral disease is closely linked to the microbiota, this disorder is closely related to the pathogenesis of oral mucosal diseases, such as oral lichen planus, recurrent aphthous ulcer, oral candidiasis and squamous-cell carcinoma. As a microorganism that is beneficial to host health, probiotics can show multi-dimensional therapeutic effects in oral mucosal diseases by targeting and regulating the immune microenvironment of the oral mucosa, inhibiting the colonization of pathogenic bacteria and repairing the barrier function.

View Article and Find Full Text PDF

Famotidine (FMD) is an H₂-receptor antagonist with limited oral bioavailability and a short plasma half-life (2.5-4 h). Silk fibroin-chitosan nanoparticles (FBN-CS-NPs) represent a novel nanocarrier approach for treating peptic ulcers, combining biocompatibility, mucoadhesiveness, and pH-sensitive release.

View Article and Find Full Text PDF

Oral lichen planus (OLP) is a chronic inflammatory disorder with limited topical treatment options and long-term corticosteroid dependency. This study investigates a novel atorvastatin-loaded hyalurosomal gel (ATV-Hyalugel) as a topical adjuvant to reduce systemic corticosteroid use in severe OLP. The objective of the study is to develop, optimize, characterize ATV-Hyalugel and evaluate its clinical efficacy in a randomized controlled clinical trial.

View Article and Find Full Text PDF

Oral ulcers are a prevalent condition globally, causing significant pain and discomfort. The unique environment of the oral cavity, characterized by its humidity and dynamic nature, in conjunction with a diverse microbiome, presents challenges for traditional treatments for oral ulcers. Chitosan has emerged as a promising therapeutic agent for this condition.

View Article and Find Full Text PDF

Objective: To evaluate the clinical efficacy and inflammatory modulation potential of Kangfuxin Liquid (KFXY; a traditional Chinese medicine recovery solution) in combination with metronidazole (MTZ) for the treatment of recurrent oral ulcers (ROU).

Methods: A retrospective cohort study was conducted using clinical data from 117 ROU patients admitted between January 2021 and January 2023. Patients were categorized into two groups: a control group (n=58) treated with MTZ oral adhesive patches alone, and an observation group (n=59) receiving KFXY plus MTZ.

View Article and Find Full Text PDF